Despite the role of PI3K/AKT signalling in promoting melanoma cell survival, BRAF/MEK inhibitors remained cytostatic in these models and there was no evidence of increased cell proliferation in the presence of PI3K/AKT activation (Fig. 3 and Figure S3). This evidence concerns the gene AKT1 and melanoma.